Niel, Belgium, January 9, 2023 – Etherna (“the Company”), a leading mRNA technologies company, announced today that Antonin (Tony) de Fougerolles has joined its board of directors as an independent member. This follows the Company’s recent Series B2 financing round to expand investment in its integrated mRNA technology platform and further pursue its new partnership-driven business strategy.
Niel, Belgium, November 10, 2022 – eTheRNA, a leading mRNA technology company, announces its nomination for the Belgian M&A Awards 2022 in the “Best Venture Capital Deal – Life Sciences 2022” category. The nomination of eTheRNA is based on its successful Series B financing in August 2022, in which eTheRNA raised €39 million of fresh capital from reputable investors.
Niel, Belgium, August 23, 2022 – eTheRNA (“the Company”), a leading mRNA technologies company, announced today that it has raised €39M in a Series B2 financing to expand investment in its integrated mRNA technology platform and further pursue its new initiatives for a partnership-driven business strategy. The round was led by Novalis LifeSciences with participation from Professor Kenneth Chien, a world-renowned expert in mRNA technology and its therapeutic applications. Existing investors, including LSP (now EQT Life Sciences), PMV, Grand Pharma, Fund+, Omega Fund, and others, also participated in the financing.
© 2023 eTheRNA | Studio Hanswijk